Details for New Drug Application (NDA): 072026
✉ Email this page to a colleague
NDA 072026 describes FENTANYL CITRATE AND DROPERIDOL, which is a drug marketed by Astrazeneca and Hospira and is included in four NDAs. Additional details are available on the FENTANYL CITRATE AND DROPERIDOL profile page.
The generic ingredient in FENTANYL CITRATE AND DROPERIDOL is droperidol; fentanyl citrate. There are five drug master file entries for this compound. Additional details are available on the droperidol; fentanyl citrate profile page.
The generic ingredient in FENTANYL CITRATE AND DROPERIDOL is droperidol; fentanyl citrate. There are five drug master file entries for this compound. Additional details are available on the droperidol; fentanyl citrate profile page.
Summary for 072026
| Tradename: | FENTANYL CITRATE AND DROPERIDOL |
| Applicant: | Astrazeneca |
| Ingredient: | droperidol; fentanyl citrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 2.5MG/ML;EQ 0.05MG BASE/ML | ||||
| Approval Date: | Apr 13, 1989 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
